Safety and feasibility of mapping and stem cell delivery in the presence of an implanted left ventricular assist device: A preclinical investigation in sheep

Texas Heart Institute Journal

Volumn 40, Issue 3, 2013, Pages 229-234

  Zheng, Yi ^a,b   Sampaio, Luiz C ^a   Li, Ke ^a   Silva, Guilherme V ^a   Cabreira Hansen, Maria ^a   Vela, Deborah ^a   Segura, Ana Maria ^a   Bovè, Christina ^a   Perin, Emerson C ^a  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

^b UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

Electromechanical mapping; Heart failure; Left ventricular assist device; Mesenchymal stem cell

Indexed keywords

STEEL;

ACUTE HEART INFARCTION; ANIMAL CELL; ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BALLOON OCCLUSION; CHRONIC DISEASE; CONTROLLED STUDY; FEASIBILITY STUDY; FLOW RATE; HEART CATHETER; HISTOPATHOLOGY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LEFT VENTRICULAR ASSIST DEVICE; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; SAFETY; SHEEP; SURGICAL STAPLING; SURGICAL WIRE; TRANSENDOCARDIAL ELECTROMECHANICAL MAPPING;

ELECTROMECHANICAL MAPPING; HEART FAILURE; LEFT VENTRICULAR ASSIST DEVICE; MESENCHYMAL STEM CELL;

ANIMALS; DISEASE MODELS, ANIMAL; EQUIPMENT DESIGN; FEASIBILITY STUDIES; HEART-ASSIST DEVICES; HEMODYNAMICS; MAGNETICS; MESENCHYMAL STEM CELL TRANSPLANTATION; MYOCARDIAL INFARCTION; PROSTHESIS DESIGN; SHEEP; SURGERY, COMPUTER-ASSISTED; TIME FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 84881125775     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. American College of Cardiology, American Heart Association. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure)[published erratum appears in J Am Cardiol 2006;47(7):1503-5]. J Am Coll Cardiol 2005; 46(6): e1-e82.
2. Hare JM, Fishman JE, Gerstenblith G, Di Fede Velazquez DL, Zambrano JP, Suncion VY, et al. Comparison of alloge-neic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 2012; 308(22):2369-2379.
3. Losordo DW, Henry TD, Davidson C, Sup Lee J, Costa MA, Bass T, et al. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res 2011;109(4):428-436.
4. Perin EC, Silva GV, Henry TD, Cabreira-Hansen MG, Moore WH, Coulter SA, et al. A randomized study of trans-endocardial injection of autologous bone marrow mononu-clear cells and cell function analysis in ischemic heart failure (FOCUS-HF). Am Heart J 2011; 161(6):1078-1087.e3.
5. Perin EC, Willerson JT, Pepine CJ, Henry TD, Ellis SG, Zhao DX, et al. Effect of transendocardial delivery of autolo-gous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA 2012;307(16):1717-1726.
6. Silva GV, Litovsky S, Assad JA, Sousa AL, Martin BJ, Vela D, et al. Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation 2005; 111 (2):150-156.
7. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyo-cyte phenotype in the adult murine heart. Circulation 2002; 105(1):93-98.
8. Perin EC, Dohmann HF, Borojevic R, Silva SA, Sousa AL, Mesquita CT, et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 2003;107(18):2294-2302.
9. Perin EC, Dohmann HF, Borojevic R, Silva SA, Sousa AL, Silva G V, et al. Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy. Circulation 2004;110(11 Suppl 1):11213-11218.
10. Tse HF, Thambar S, Kwong YL, Rowlings P, Bellamy G, McCrohon J, et al. Safety of catheter-based intramyocardi-al autologous bone marrow cells implantation for therapeutic angiogenesis. Am J Cardiol 2006;98(1):60-62.
11. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002;105(4):539-542.
12. Perin EC, Silva GV, Sarmento-Leite R, Vaughn WK, Fish RD, Ferguson JJ 3rd. Left ventricular electromechanical mapping: preliminary evidence of electromechanical changes after successful coronary intervention. Am Heart J 2002;144 (4):693-701.
13. Perin EC, Silva GV, Assad JA, Vela D, Buja LM, Sousa AL, et al. Comparison of intracoronary and transendocardial delivery of allogeneic mesenchymal cells in a canine model of acute myocardial infarction. J Mol Cell Cardiol 2008;44(3):486-495.
14. Kang WJ, Kang HJ, Kim HS, Chung JK, Lee MC, Lee DS. Tissue distribution of 18F-FDG-labeled peripheral hemato-poietic stem cells after intracoronary administration in patients with myocardial infarction [published erratum appears in J Nucl Med 2006;47(9):1399]. J Nucl Med 2006;47(8):1295-1301.
15. Cheng Y, Yi G, Conditt GB, Sheehy A, Kolodgie FD, Tellez A, et al. Catheter-based endomyocardial delivery of mesen-chymal precursor cells using 3D echo guidance improves cardiac function in a chronic myocardial injury ovine model. Cell Transplant 2012 Oct 25. [Epub ahead of print].